EpiAxis joins Tech Tuesday panel discussion

EpiAxis joins Tech Tuesday panel discussion

EpiAxis Therapeutics CEO Dr Jeremy Chrisp this week joined Tech Tuesdays, a Canadian Securities Exchange virtual showcase that features in-depth discussions with companies shaking up the technology industry. The episode – Precision Medicine in Cancer Treatment...
EpiAxis presents at BioPharm America 2022

EpiAxis presents at BioPharm America 2022

EpiAxis Therapeutics recently presented at BioPharm America 2022, part of Biotech Week Boston, giving investors an update on the company’s progress in the epigenetic space. BioPharm America is a conference where the new wave of life science innovators partner to...
EpiAxis enters strategic partnership with UHN

EpiAxis enters strategic partnership with UHN

EpiAxis Therapeutics and University Health Network (UHN) – Canada’s largest and leading research hospital – have entered into a collaboration to study a new approach to prostate cancer treatment. As part of the agreement, EpiAxis Therapeutics will supply...
EpiAxis highlights – July 2022

EpiAxis highlights – July 2022

July offered valuable opportunities for EpiAxis Therapeutics to update venture capitalists, corporate investors, private investors and investment bankers on its latest epigenetic findings. The company is currently working with The Sage Group to raise US$12million to...